AzTrials
AzTrials

Diabetes Type 2MITOSTRENGTHNCT07828847

Involvement of Muscle Mitochondrial Dysfunction in Frailty in Older Adults. Role of Exercise

A study testing Short-duration resistance training in people with Diabetes Type 2 and Frail Elderly Syndrome, run by Fundación para la Investigación del Hospital Clínico de Valencia at 1 site in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to investigate the role of skeletal muscle mitochondrial dysfunction in the development of frailty in older adults and to evaluate whether a short-term, supervised resistance training intervention can improve skeletal muscle health and physical function. Read more about this study

Who is it for?
Ages 18 to 83 yearsHealthy volunteers can take part
What is being tested?
Short-duration resistance training
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteSpain
Study dates
29 Jan 2022to 31 Jul 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 83 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy young adults (18-35 years old)
  • Without any pathology or treatment
  • Healthy older adults (65 years or older)
  • Not currently enrolled in a resistance training program
  • Age over 65 years
  • Diagnosis of frailty or robustness
Show all 10Show fewer
  • Diagnosis of type 2 diabetes mellitus
  • Glycosylated hemoglobin (HbA1c) less than 9%
  • Treatment with metformin
  • Not currently enrolled in a resistance training program

Who cannot join

  • Pregnancy or suspected pregnancy
  • Body mass index greater than 35 kg/m2
  • Treatment within the last 30 days with oral corticosteroids
  • Edema or severe fluid regulation disorders that could alter bioimpedance results
  • Allergy to the local anesthetic mepivacaine
  • Prostheses, metal implants, or surgical staples lodinated or barium contrast for other imaging tests within the last 7 days
Show all 29Show fewer
  • Decompensated and uncontrolled chronic diagnoses
  • Body mass index greater than 35 kg/m2
  • Treatment within the last 30 days with oral corticosteroids
  • Systemic diseases, active oncological disease, liver cirrhosis, untreated hypothyroidism, or severe chronic obstructive pulmonary disease (COPD).
  • Severe edema or fluid regulation disorders that could alter bioimpedance results
  • Allergy to the local anesthetic mepivacaine
  • Prostheses, metal implants, or surgical staples Iodinated or barium contrast for other imaging tests in the last 7 days
  • Diagnosis of pre-frailty
  • Age over 80 years
  • Body mass index greater than 35 kg/m2
  • Time since onset of diabetes mellitus type 2 less than 10 years
  • Treatment with insulin
  • Treatment with allopurinol
  • Treatment with anticoagulant or antiplatelet drugs
  • Treatment within the last 30 days with oral corticosteroids
  • Advanced chronic complications of diabetes mellitus type 2 :
  • Renal failure (clearance <30 ml/min/m2) Macroalbuminuria greater than 200 mg/g Ischemic vascular diseases (acute myocardial infarction) Myocardial infarction, angina, stroke) Proliferative retinopathy or laser therapy Ulcerated diabetic foot or lower limb amputations, except for digital amputations
  • Systemic diseases, active oncological disease, liver cirrhosis, untreated hypothyroidism, or severe chronic obstructive pulmonary disease
  • Physical limitations in the lower limbs (acute or acute-on-chronic inflammatory processes, limited joint range of motion, chronic pain (visual analogue scale for pain > or = 4, etc.)
  • Senile dementia
  • Edema or severe fluid regulation disorders that may alter bioimpedance results
  • Allergy to the local anesthetic mepivacaine
  • Pacemaker, metallic prostheses or implants, surgical staples, and radiopaque tubes or catheters Iodinated or barium contrast for other imaging tests within the last 7 days

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Maria Carmen Gómez Cabrera, Doctor in Physiology contact

+34-666871805

carmen.gomez@uv.es

Spain1 site, 1 recruiting
  • University of Valencia/Hospital Clínico Universitario de València,

    Valencia, 46010

    Maria Carmen Gómez Cabrera, Doctor in Physiology, +34-666871805, carmen.gomez@uv.es

    Recruiting

Other trials in Spain

About this study

This study aims to investigate the role of skeletal muscle mitochondrial dysfunction in the development of frailty in older adults and to evaluate whether a short-term, supervised resistance training intervention can improve skeletal muscle health and physical function.

Frailty is a common age-related condition associated with increased vulnerability to disability, hospitalisation, and loss of independence. It is characterised by features that may include weakness, fatigue, reduced physical activity, and slower walking speed. Mitochondrial dysfunction in skeletal muscle may contribute to the development of frailty and may be further influenced by chronic conditions such as type 2 diabetes mellitus (T2DM), which are associated with metabolic alterations, inflammation, oxidative stress, and insulin resistance.

Read more

Resistance training is an effective strategy to counteract age-related declines in muscle strength and physical function. However, the cellular and molecular mechanisms linking resistance training to improvements in mitochondrial function, skeletal muscle health, and resilience in older adults remain incompletely understood.

The study will include approximately 120 participants comprising older adults with T2DM, healthy older adults, and young healthy controls.

All participants will complete a 6-week supervised resistance training intervention, consisting of two sessions per week.

Assessments performed before and after the intervention will include body composition, muscle morphology, physical performance, muscle strength, frailty, and blood-based biomarkers. Peripheral blood mononuclear cells (PBMCs) will be used to assess mitochondrial function, and plasma samples will be used for proteomic profiling. Stool samples will be collected for analysis of gut microbiota.

A subset of participants will undergo skeletal muscle biopsies of the vastus lateralis at baseline and after the intervention. Muscle samples will be used to assess mitochondrial oxidative phosphorylation capacity, mitochondrial quality-control proteins, muscle fibre morphology, cell-type-specific transcriptomic profiles using single-nucleus RNA sequencing, and chromatin accessibility using ATAC-seq.

The study will provide an integrated assessment of the effects of resistance training on mitochondrial function, skeletal muscle biology, physical function, frailty, circulating biomarkers, and gut microbiota. These findings may help clarify the biological mechanisms through which resistance training influences muscle health and resilience during ageing and in older adults with T2DM.

Read the detailed description

Background and Rationale:

Frailty is a multifactorial geriatric syndrome characterized by a decline in physiological reserves across multiple systems, leading to reduced resilience, weakness, and increased vulnerability to stressors such as acute illness, injury, or surgery. Clinically, frailty manifests as diminished strength, slowed mobility, exhaustion, and unintentional weight loss, often culminating in disability, hospitalization, and premature mortality. Among its core biological features, skeletal muscle deterioration, encompassing losses in muscle mass, contractile function, and regenerative capacity, plays a central role in the onset and progression of functional impairment and dependence in older adults.

At the cellular level, mitochondrial dysfunction has emerged as a key pathophysiological driver of frailty and sarcopenia. Mitochondria are essential for energy production, redox balance, and regulation of calcium homeostasis, apoptosis and inflammation. With aging, mitochondrial content, dynamics, and efficiency decline, leading to reduced ATP generation, increased reactive oxygen species (ROS) production, and accumulation of damaged mitochondrial DNA (mtDNA). These alterations compromise muscle bioenergetics and promote catabolic pathways that accelerate muscle atrophy. Moreover, defective mitophagy, an essential quality control process, leads to the persistence of dysfunctional organelles, perpetuating oxidative stress and inflammation.

Systemic metabolic disturbances further exacerbate these mitochondrial deficits. A chronic condition such as type 2 diabetes mellitus (T2DM) is frequently associated with frailty and share common mechanisms. Increased levels of pro-inflammatory cytokines (e.g., IL-6, TNF-α) and mitochondrial stress markers signal ongoing tissue damage and maladaptive stress responses. These interactions between metabolic dysregulation, inflammation, and mitochondrial dysfunction form a self-reinforcing cycle that underlies the molecular pathogenesis of frailty.

Exercise training, and particularly resistance exercise, is among the most potent non-pharmacological interventions to counteract frailty-related declines. Regular exercise improves muscle mass and strength, enhances glucose and lipid metabolism, and promotes mitochondrial biogenesis and function through activation of key molecular pathways. Furthermore, exercise induces the release of myokines that mediate intercellular communication between muscle and distant organs, influencing systemic metabolism, inflammation, and repair processes. However, despite well-established clinical benefits, the molecular and cellular mechanisms by which exercise remodels mitochondrial networks and restores metabolic homeostasis in frail or metabolically compromised individuals remain incompletely understood.

Elucidating how exercise modulates mitochondrial quality control, energy metabolism, and signaling pathways in the context of frailty could reveal new therapeutic targets to delay or reverse physiological decline. Integrating metabolic markers with molecular indicators of mitochondrial stress and muscle-derived factors offers a multidimensional approach to understanding the bioenergetic and inflammatory signatures of frailty and their reversibility through targeted interventions.

Study Objectives:

This project aims to:

  1. Determine the contribution of skeletal muscle mitochondrial dysfunction to frailty in older adults, including those with T2DM.
  2. Evaluate the effects of a 6-week supervised resistance training program on functional, molecular, and metabolic outcomes.
  3. Characterize adaptations within the perimuscular interstitial microenvironment (fibroblasts, immune cells, vascular, neural and muscle stem cells as well as extracellular matrix components) that may mediate exercise-induced improvements in muscle health.

Through these objectives, the study seeks to integrate clinical, physiological, and molecular analyses to uncover mechanisms linking mitochondrial remodelling, aging, and exercise adaptation

Study Design:

This is a longitudinal, interventional study including 120 participants divided into three groups:

  • Older adults with T2DM (≥65 years) - 40 participants
  • Healthy older adults (≥65 years) - 40 participants
  • Young healthy adults (19-35 years) - 40 participants (controls) All participants will complete baseline assessments, a 6-week supervised resistance training program, and post-intervention evaluations. Optional muscle biopsies will be obtained from participants who consent before and after training.

Intervention:

Participants will undergo a 6-week progressive resistance training program targeting the quadriceps muscles, consisting of two sessions per week (a total of 12 sessions), each lasting 30-50 minutes.

  • Exercises include leg press and knee extension, progressing from submaximal to near-maximal effort as tolerated.
  • Training intensity and progression will be individualised according to functional capacity.
  • All sessions will be supervised by qualified exercise specialists to ensure safety and adherence.

This short, structured, and closely monitored training protocol was designed to be both safe and feasible for older adults with varying levels of frailty or diabetes.

Assessments and Procedures:

Baseline and Post-Intervention Evaluations:

Participants will undergo comprehensive testing before and after the exercise program, including:

  • Blood sampling for metabolic, inflammatory, and aging biomarkers.
  • Body composition analysis using DXA, ultrasound, and bioimpedance.
  • Functional assessments of strength, balance, gait speed, and mobility.
  • Stool sampling for gut microbiota composition.
  • Optional muscle biopsies (quadriceps) under local anesthesia for mitochondrial and tissue-level analyses.

Muscle Biopsy Analyses

Muscle tissue samples will be used to examine:

  • Mitochondrial function, oxidative stress, and biogenesis markers.
  • Cellular and molecular characteristics of the perimuscular niche via single-nuclei and histological analyses.
  • Changes in fibrosis, immune infiltration, vascular density, and extracellular matrix remodelling following exercise.

All biopsy procedures will be performed by trained clinicians following hospital safety protocols, with local anaesthesia and post-procedure monitoring.

Outcomes and Data Integration:

The study will generate a comprehensive dataset encompassing:

  • Clinical and functional outcomes: muscle strength, mobility, balance, and composite frailty scores.
  • Molecular and biochemical measures: mitochondrial respiration, oxidative stress and inflammatory markers, and pathways related to muscle regeneration.
  • Circulating biomarkers: metabolic, inflammatory, and aging-related factors.
  • Microbiome analyses: gut bacterial diversity and composition.
  • Cross-sectional comparisons: differences across age and diabetes status.
  • Longitudinal effects: pre- vs. post-intervention changes in functional and molecular endpoints.

This integrated approach will allow exploration of mechanistic links between exercise-induced mitochondrial remodelling, systemic inflammation, and functional improvements.

Safety Considerations:

The exercise program carries minimal risk and will be supervised at all times. Potential risks include mild muscle soreness or fatigue. Blood sampling may cause minor bruising or lightheadedness. Muscle biopsy, when performed, carries a small risk of pain, bleeding, or infection; all procedures will be conducted by trained clinical personnel with appropriate monitoring and follow-up.

Participants' safety will be prioritised throughout the study, with adherence logs, post-biopsy monitoring, and regular communication with healthcare providers.

Potential Benefits:

Participants may experience improvements in strength, balance, and mobility, as well as greater awareness of their health and functional capacity.

Beyond individual benefits, this project is expected to provide key insights into:

  • The role of mitochondrial dysfunction and diabetes in age-related muscle decline.
  • The cellular mechanisms underlying exercise-induced rejuvenation of skeletal muscle.
  • Evidence-based strategies for designing personalised exercise programs to delay or prevent frailty.

Significance and Expected Impact:

By comparing diabetic and non-diabetic older adults with younger controls, this study will clarify the contribution of mitochondrial dysfunction and systemic metabolic stress to muscle aging and functional decline. It will also identify how short-term, supervised resistance training promotes beneficial adaptations within muscle fibers and their surrounding microenvironment.

The results will contribute to developing practical, safe, and effective interventions to maintain independence, improve quality of life, and reduce healthcare burden in aging populations. Ultimately, this project aims to bridge the gap between basic mitochondrial biology and translational geroscience, providing new insights into the prevention and management of frailty in older adults.

Being tested
Short-duration resistance training
Keywords
Diabetes type 2, Frailty, Mitochondrial function, Skeletal Muscle, Physical Function
Medical subject headings
Diabetes Mellitus, Type 2, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Short-duration resistance trainingOther

    The exercise program will be personalized (based on functional status). This program will consist of 12 sessions spread over 6 weeks, two days a week, and will increase in duration (30-50 minutes). The lower body muscle group, targeting the quadriceps, will be trained with two exercises: leg press and quadriceps extension. The training intensity will be submaximal, progressing toward maximum. All patient groups, both controls and cases, will receive the same type of training.

Study groups in NCT07828847
Study groupRoleWhat they receive
Group of healthy trained old peopleActive comparatorElderly patient without diagnosis of type 2 diabetes mellitus
Receives: Other: Short-duration resistance training
Group of type 2 diabetic trained old patientsActive comparatorElderly patient diagnosed with type 2 diabetes mellitus
Receives: Other: Short-duration resistance training
Group of healthy trained young peopleActive comparatorYoung healthy control subjects
Receives: Other: Short-duration resistance training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Mitochondrial Oxidative Phosphorylation (OXPHOS) Capacity in Skeletal Muscle

    Mitochondrial oxidative phosphorylation capacity will be assessed in permeabilised skeletal muscle fibre bundles obtained from vastus lateralis biopsies using high-resolution respirometry (Oxygraph-2k, Oroboros Instruments). OXPHOS capacity will be expressed as oxygen flux normalised to muscle tissue wet weight (pmol O₂·s-¹·mg-¹ wet tissue).

    Measured: Baseline and after 6 weeks of supervised resistance training

  2. Change in Mitochondrial Oxidative Phosphorylation (OXPHOS) Capacity in Peripheral Blood Mononuclear Cells (PBMCs)

    Mitochondrial oxidative phosphorylation capacity will be assessed in permeabilised peripheral blood mononuclear cells (PBMCs) using high-resolution respirometry (Oxygraph-2k, Oroboros Instruments). OXPHOS capacity will be expressed as oxygen flux normalised to cell number (pmol O₂·s-¹·10⁶ cells-¹).

    Measured: Baseline and after 6 weeks of supervised resistance training

Secondary outcomes (17)
  1. Change in Mitochondrial Quality Control Protein Expression in Skeletal Muscle

    Protein expression of selected markers involved in mitochondrial dynamics, mitophagy, and biogenesis, including MFN1, MFN2, DRP1, PINK1, PARKIN, PGC-1α, and TFAM, will be assessed in vastus lateralis muscle biopsies by Western blot. Protein abundance will be quantified by densitometry, normalised to an appropriate loading control, and expressed as fold change relative to baseline.

    Measured: Baseline and after 6 weeks of supervised resistance training

  2. Change in Whole-Body Lean Mass

    Whole-body lean mass will be assessed by dual-energy X-ray absorptiometry (DXA) and expressed in kilograms (kg).

    Measured: Baseline and after 6 weeks of supervised resistance training

  3. Change in Whole-Body Fat Mass

    Whole-body fat mass will be assessed by dual-energy X-ray absorptiometry (DXA) and expressed in kilograms (kg).

    Measured: Baseline and after 6 weeks of supervised resistance training

  4. Change in 6-Minute Walk Test Distance

    Functional exercise capacity will be assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes will be recorded in metres (m), with a greater distance indicating better functional exercise capacity.

    Measured: Baseline and after 6 weeks of supervised resistance training

  5. Change in Blood Glucose-6-Phosphate Dehydrogenase (G6PD) Activity

    Glucose-6-phosphate dehydrogenase (G6PD) activity will be measured in blood as a systemic redox-related biomarker and expressed as units per gram of haemoglobin (U/g Hb).

    Measured: Baseline and after 6 weeks of supervised resistance training

  6. Change in Skeletal Muscle Cell-Type-Specific Transcriptomic Profiles

    Single-nucleus RNA sequencing will be performed on vastus lateralis muscle biopsies to characterise cell-type-specific gene expression profiles in skeletal muscle. Transcript abundance will be quantified as normalised gene expression counts within identified cell populations.

    Measured: Baseline and after 6 weeks of supervised resistance training

  7. Change in Gut Microbiota Alpha Diversity

    Gut microbiota alpha diversity will be assessed using the Shannon diversity index. The Shannon index is unitless, with higher values indicating greater microbial diversity.

    Measured: Baseline and after 6 weeks of supervised resistance training

  8. Change in Quadriceps Muscle Thickness

    Quadriceps muscle thickness will be assessed by ultrasound and expressed in millimetres (mm).

    Measured: Baseline and after 6 weeks of supervised resistance training

  9. Change in Skeletal Muscle Fibre Cross-Sectional Area

    Skeletal muscle fibre cross-sectional area will be assessed by histological analysis of vastus lateralis muscle biopsies and expressed in square micrometres (µm²).

    Measured: Baseline and after 6 weeks of supervised resistance training

  10. Change in Short Physical Performance Battery (SPPB) Score

    Lower-extremity physical function will be assessed using the Short Physical Performance Battery (SPPB), which includes standing balance, usual gait speed, and repeated chair stands. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance.

    Measured: Baseline and after 6 weeks of supervised resistance training

  11. Change in FallSkip Test Performance Time

    Functional mobility and fall-related performance will be assessed using the FallSkip test. Time to complete the test will be recorded in seconds (s), with a shorter time indicating better performance.

    Measured: Baseline and after 6 weeks of supervised resistance training

  12. Change in Blood Malondialdehyde (MDA) Levels

    Malondialdehyde (MDA) levels will be measured in blood as a marker of systemic lipid peroxidation and expressed in micromoles per litre (µmol/L).

    Measured: Baseline and after 6 weeks of supervised resistance training

  13. Change in Fried Frailty Phenotype Score

    Frailty status will be assessed using the Fried Frailty Phenotype, based on five criteria: unintentional weight loss, self-reported exhaustion, low physical activity, slow walking speed, and weakness. The total score ranges from 0 to 5, with higher scores indicating greater frailty.

    Measured: Baseline and after 6 weeks of supervised resistance training

  14. Change in Frailty Classification Assessed by the Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI)

    Frailty will be assessed using the Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI), which combines fatigue, loss of appetite, grip strength, functional difficulties, and physical activity. Participants will be classified as non-frail, pre-frail, or frail according to the SHARE-FI algorithm, with higher frailty categories indicating greater frailty.

    Measured: Baseline and after 6 weeks of supervised resistance training

  15. Change in Quadriceps Extension 3-Repetition Maximum (3RM)

    Quadriceps muscle strength will be assessed using the 3-repetition maximum (3RM) during the quadriceps extension exercise. The maximum load successfully completed for three repetitions will be recorded in kilograms (kg), with higher values indicating greater muscle strength.

    Measured: Baseline and after 6 weeks of supervised resistance training

  16. Change in Skeletal Muscle Chromatin Accessibility Profiles Assessed by ATAC-seq

    Chromatin accessibility will be assessed in skeletal muscle samples using Assay for Transposase-Accessible Chromatin sequencing (ATAC-seq). Genome-wide chromatin accessibility profiles will be quantified using normalised accessibility signals across identified regulatory regions.

    Measured: Baseline and after 6 weeks of supervised resistance training

  17. Change in Plasma Proteomic Profiles

    Plasma proteomic profiling will be performed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to characterise changes in circulating protein abundance. Protein abundance will be quantified and expressed as normalised relative abundance values.

    Measured: Baseline and after 6 weeks of supervised resistance training

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2026
  2. Study start29 Jan 2022
  3. Primary completion31 Jul 2028 (estimated)
  4. Study completion31 Jul 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07828847
Sponsor's protocol ID
MITOSTRENGTH
Acronym
MITOSTRENGTH
Status last verified
Sep 2026
First submitted
29 May 2025
Last updated
18 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (IPD) that underlie the results reported in this study will be shared, including data on baseline characteristics, frailty scores, functional assessments, mitochondrial, enzimatic and biochemical parameters. No identifiable information will be included. The data will be available beginning 12 months following publication of the main results. Access to the de-identified IPD will be provided to researchers whose proposed use of the data has been approved by an independent review committee. The requesting investigators must provide a methodologically sound proposal and agree to use the data for academic, non-commercial purposes only. Data will be made available through an institutional repository or upon request.

Publications

  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.

    PubMed 30312372
  • Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.

    PubMed 20392703
  • Ruiz Comellas A, Pera G, Baena Diez JM, Mundet Tuduri X, Alzamora Sas T, Elosua R, Toran Monserrat P, Heras A, Fores Raurell R, Fuste Gamisans M, Fabrega Camprubi M. [Validation of a Spanish Short Version of the Minnesota Leisure Time Physical Activity Questionnaire (VREM)]. Rev Esp Salud Publica. 2012 Oct;86(5):495-508. doi: 10.4321/S1135-57272012000500004. Spanish.

    PubMed 23223762
  • Srere PA. An eclectic view of metabolic regulation: control of citrate synthase activity. Adv Enzyme Regul. 1970;9:221-33. doi: 10.1016/s0065-2571(71)80046-8. No abstract available.

    PubMed 4329195
  • Lopez-Lluch G, Hunt N, Jones B, Zhu M, Jamieson H, Hilmer S, Cascajo MV, Allard J, Ingram DK, Navas P, de Cabo R. Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency. Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1768-73. doi: 10.1073/pnas.0510452103. Epub 2006 Jan 30.

    PubMed 16446459
  • WALLER HD, LOHR GW, TABATABAI M. [Hemolysis and absence of glucose-6-phosphate dehydrogenase in erythrocytes; an enzyme abnormality of erythrocytes]. Klin Wochenschr. 1957 Oct 15;35(20):1022-7. doi: 10.1007/BF01488728. No abstract available. German.

    PubMed 13515125
  • Bauerl C, Collado MC, Zuniga M, Blas E, Perez Martinez G. Changes in cecal microbiota and mucosal gene expression revealed new aspects of epizootic rabbit enteropathy. PLoS One. 2014 Aug 22;9(8):e105707. doi: 10.1371/journal.pone.0105707. eCollection 2014.

    PubMed 25147938
  • Silva JSC, Seguro CS, Naves MMV. Gut microbiota and physical exercise in obesity and diabetes - A systematic review. Nutr Metab Cardiovasc Dis. 2022 Apr;32(4):863-877. doi: 10.1016/j.numecd.2022.01.023. Epub 2022 Jan 29.

    PubMed 35227549
  • Pasini E, Corsetti G, Assanelli D, Testa C, Romano C, Dioguardi FS, Aquilani R. Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes. Minerva Med. 2019 Feb;110(1):3-11. doi: 10.23736/S0026-4806.18.05589-1.

    PubMed 30667205
  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.

    PubMed 19414839
  • Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011 Jul;40(4):423-9. doi: 10.1093/ageing/afr051. Epub 2011 May 30.

    PubMed 21624928
  • Perez-Ros P, Sanchis-Aguado MA, Dura-Gil JV, Martinez-Arnau FM, Belda-Lois JM. FallSkip device is a useful tool for fall risk assessment in sarcopenic older community people. Int J Older People Nurs. 2022 May;17(3):e12431. doi: 10.1111/opn.12431. Epub 2021 Oct 14.

    PubMed 34652070
  • Hernandes NA, Wouters EF, Meijer K, Annegarn J, Pitta F, Spruit MA. Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J. 2011 Aug;38(2):261-7. doi: 10.1183/09031936.00142010. Epub 2010 Dec 22.

    PubMed 21177838
  • Chen X, Abbey S, Bharmal A, Harris S, Hudson E, Krinner L, Langan E, Maling A, Nijran J, Street H, Wooley C, Billeter R. Neurovascular structures in human vastus lateralis muscle and the ideal biopsy site. Scand J Med Sci Sports. 2019 Apr;29(4):504-514. doi: 10.1111/sms.13369. Epub 2019 Jan 27.

    PubMed 30561846

Questions about this trial

What is this clinical trial studying?

A study testing Short-duration resistance training in people with Diabetes Type 2 and Frail Elderly Syndrome, run by Fundación para la Investigación del Hospital Clínico de Valencia at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Maria Carmen Gómez Cabrera, Doctor in Physiology (+34-666871805, carmen.gomez@uv.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Mitochondrial Oxidative Phosphorylation (OXPHOS) Capacity in Skeletal Muscle (time frame: Baseline and after 6 weeks of supervised resistance training). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07828847, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in